尿激酶型纤溶酶原激活剂在髓母细胞瘤中的表达及意义  

Expression and Significance of Urokinase type Plasminogen Activator in Medulloblastoma

作　　者：王勇[1] 毛伯镛[1] 张尚福[2] 程宏伟[1] 

机构地区：[1]华西医科大学附属第一医院神经外科,成都610041 [2]华西医科大学附属第一医院病理科,成都610041

出　　处：《华西医科大学学报》2001年第3期376-378,共3页Journal of West China University of Medical Sciences

摘　　要：目的　研究尿激酶型纤溶酶原激活剂 (u PA)在髓母细胞瘤中的表达及临床意义。方法　应用免疫组化 L SAB法检测 5 0例髓母细胞瘤中 u PA的表达 ,结合临床随访 ,使用 Cox回归分析。结果　 u PA染色定位于肿瘤细胞和血管内皮细胞。 Cox回归分析显示 u PA是影响生存时间的一个独立的预后因子 ,它与预后存在一定的负相关关系。结论　 uObjective To detect the expression and evaluate the clinical significance of urokinase type plasminogen activator (uPA) in medulloblastoma. Methods LSAB (labelled streptavidin biotin method) immunohistochemical technique was applied for detecting the expression of uPA in 50 patients with medulloblastoma, and a follow up survey with Cox regression analysis was made. Results The staining for uPA was localized on tumor cells and endothelial cells. Cox regression analysis showed that uPA was an independent prognostic factor affecting survival and it had a negative correlation with the prognosis. Conclusion uPA appears to be an independent marker for predicting the prognosis of medulloblastoma.

关 键 词：髓母细胞瘤 尿激酶型纤溶酶原激活剂 免疫组织化学 预后 

分 类 号：R739.41[医药卫生—肿瘤]